Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update

Exclusively licensed Senlang’s CD7-Targeted lentiviral in vivo CAR-T platform following initial Phase 1 results with lead BCMA/GPRC5D candidate TPST-4903Secured access to additional capital through an equity line of credit with Lincoln Park Capital Fund of up to $50.0 million and a private placemen…